Maxim analyst Naz Rahman downgraded Alimera Sciences (ALIM) to Hold from Buy after ANI Pharmaceuticals (ANIP) agreed to acquire Alimera for $5.50 per share in cash upfront and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALIM:
- Alimera Sciences Set for Merger with ANI Pharmaceuticals
- ANI Pharmaceuticals sees ‘substantial accretion’ from Alimera Sciences deal
- ANI Pharmaceuticals to acquire Alimera Sciences for $381M upfront
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Alimera Sciences reports Q1 EPS (12c), consensus (6c)